Published in Thromb Haemost on August 01, 2001
Evaluation of deep vein thrombosis with multidetector row CT after orthopedic arthroplasty: a prospective study for comparison with Doppler sonography. Korean J Radiol (2008) 0.99
Screening for deep vein thrombosis after periacetabular osteotomy in adult patients: is it necessary? Clin Orthop Relat Res (2014) 0.80
Investigation of the veins in patients with Behçet's disease with no known vascular event by Doppler ultrasonography. Rheumatol Int (2010) 0.79
Venous thromboembolic prophylaxis for hip fractures. Osteoporos Int (2010) 0.78
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med (1997) 3.35
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost (2010) 2.08
Deep-vein thrombosis. Lancet (1999) 1.98
Psychological aspects and coping in haemophilic patients: a case-control study. Haemophilia (2003) 1.98
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost (2003) 1.95
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75
Features of essential thrombocythaemia in childhood: a study of five children. Br J Haematol (2000) 1.67
Decision analysis for cancer screening in idiopathic venous thromboembolism. J Thromb Haemost (2005) 1.65
Screening for occult cancer in patients with acute deep vein thrombosis or pulmonary embolism. J Thromb Haemost (2004) 1.63
Fibrinolytic variables in patients with recurrent venous thrombosis: a prospective cohort study. Thromb Haemost (2001) 1.58
Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med (1997) 1.57
The metabolic syndrome and the risk of venous thrombosis: a case-control study. J Thromb Haemost (2006) 1.55
Risk stratification and outcomes in hemodynamically stable patients with acute pulmonary embolism: a prospective, multicentre, cohort study with three months of follow-up. J Thromb Haemost (2009) 1.55
Clinical outcome in patients with venous thromboembolism and hidden cancer: findings from the RIETE Registry. J Thromb Haemost (2007) 1.54
Screening for occult cancer in patients with idiopathic venous thromboembolism: yes. J Thromb Haemost (2003) 1.54
Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview. Thromb Haemost (2000) 1.51
The long-term risk of cancer in patients with a first episode of venous thromboembolism. J Thromb Haemost (2008) 1.50
Interaction of asialo von Willebrand factor with glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and mediates platelet aggregation. J Clin Invest (1985) 1.44
Mild bleeding diathesis in a boy with combined severe haemophilia B (C(10400)-->T) and heterozygous factor V Leiden. Haemophilia (2001) 1.43
Antiphospholipid antibodies, recurrent thromboembolism, and intensity of warfarin anticoagulation. Thromb Haemost (1996) 1.42
Use of an algorithm for administering subcutaneous heparin in the treatment of deep venous thrombosis. Ann Intern Med (1998) 1.41
Factor VIII/von Willebrand factor abnormalities during L-asparaginase treatment in patients with acute lymphoblastic leukemia. Acta Haematol (1988) 1.40
Indirect study of thrombopoiesis (TPO, reticulated platelets, glycocalicin) in patients with hereditary macrothrombocytopenia. Eur J Haematol (2000) 1.40
The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica (1997) 1.39
Duration of anticoagulation and risk of recurrent thromboembolism in carriers of factor V Leiden or prothrombin mutation. J Thromb Haemost (2008) 1.39
Prothrombin time using thromboplastins of different origin in hemophilia BM patients. Am J Hematol (1994) 1.38
Clinical and laboratory expression of associated thrombophilic conditions (homozygous/heterozygous factor V Leiden mutation and heterozygous prothrombin variant 20210A) in an Italian family. Blood Coagul Fibrinolysis (2000) 1.38
Definition of post-thrombotic syndrome of the leg for use in clinical investigations: a recommendation for standardization. J Thromb Haemost (2009) 1.35
von Willebrand factor interaction with the glycoprotein IIb/IIa complex. Its role in platelet function as demonstrated in patients with congenital afibrinogenemia. J Clin Invest (1986) 1.28
Distribution of thrombosis in patients with symptomatic deep vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med (1993) 1.26
Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost (1999) 1.23
Interaction of purified type IIB von Willebrand factor with the platelet membrane glycoprotein Ib induces fibrinogen binding to the glycoprotein IIb/IIIa complex and initiates aggregation. Proc Natl Acad Sci U S A (1985) 1.23
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
Autoimmune thrombocytopenia (AITP) and thyroid autoimmune disease (TAD): overlapping syndromes? Clin Exp Immunol (1998) 1.18
Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med (1994) 1.17
An unexpectedly high rate of pulmonary embolism in patients with superficial thrombophlebitis of the thigh. J Vasc Surg (1999) 1.13
Acute coronary disease in essential thrombocythemia and polycythemia vera. J Intern Med (1998) 1.10
It is not sure yet whether the nt 20210 G to A prothrombin polymorphism represents a cause of familial venous thrombophilia. Blood Coagul Fibrinolysis (1999) 1.08
Relation between quality of anticoagulant treatment and the development of the postthrombotic syndrome. J Thromb Haemost (2005) 1.07
Prothrombotic activity of oral contraceptives in patients with congenital thrombophilia varies with the defect. Clin Appl Thromb Hemost (2001) 1.07
Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer (1998) 1.07
Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol (2005) 1.06
Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial. World J Surg (1997) 1.06
Effects of early maternal separation of lambs and rearing with minimal and maximal human contact on meat quality. Meat Sci (2005) 1.04
Fatal bleeding in patients receiving anticoagulant therapy for venous thromboembolism: findings from the RIETE registry. J Thromb Haemost (2010) 1.04
Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke (1995) 1.04
Thrombosis and hemorrhage in thrombocytosis: evaluation of a large cohort of patients (357 cases). J Med (1991) 1.02
The incidence of venous thromboembolism following gynecologic laparoscopy: a multicenter, prospective cohort study. J Thromb Haemost (2006) 1.02
Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein thrombosis. Blood (2000) 1.02
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Type IIB von Willebrand factor with normal sialic acid content induces platelet aggregation in the absence of ristocetin. Role of platelet activation, fibrinogen, and two distinct membrane receptors. J Clin Invest (1987) 1.01
The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost (1996) 1.01
Cancer and venous thromboembolism. Am Heart J (1996) 1.01
Rheological and fibrinolytic findings in multiple sclerosis. J Neurol Neurosurg Psychiatry (1981) 1.00
Venous thrombosis during pregnancy: leg and trimester of presentation. Thromb Haemost (1992) 1.00
The incidence of venous thromboembolism in asymptomatic carriers of a deficiency of antithrombin, protein C, or protein S: a prospective cohort study. Blood (1999) 1.00
Proposal of a standard approach to dental extraction in haemophilia patients. A case-control study with good results. Haemophilia (2000) 0.99
The post-thrombotic syndrome. Curr Opin Pulm Med (2000) 0.98
EDTA dependent pseudothrombocytopenia caused by antibodies against the cytoadhesive receptor of platelet gpIIB-IIIA. J Clin Pathol (1994) 0.98
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol (2006) 0.97
Antithrombin III (AT III) Padua2: a "new" congenital abnormality with defective heparin co-factor activities but no thrombotic disease. Blut (1983) 0.97
Cancer and venous thromboembolism: an overview. Haematologica (1999) 0.96
A comparison of compression ultrasound with color Doppler ultrasound for the diagnosis of symptomless postoperative deep vein thrombosis. Arch Intern Med (1997) 0.96
A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation (1993) 0.95
Platelet-derived factor Va/Va Leiden cofactor activities are sustained on the surface of activated platelets despite the presence of activated protein C. Blood (1998) 0.95
Vein abnormalities and the post-thrombotic syndrome. J Thromb Haemost (2005) 0.95
Can causes of false-normal D-dimer test [SimpliRED] results be identified? Thromb Res (2003) 0.94
Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost (2005) 0.94
Risk factors for thrombosis in patients with immune mediated heparin-induced thrombocytopenia. J Intern Med (2002) 0.93